Radiation-inducible immunotherapy for cancer: Senescent tumor cells as a cancer vaccine

Molecular Therapy

Volumn 20, Issue 5, 2012, Pages 1046-1055

  Meng, Yuru ^a   Efimova, Elena V ^a   Hamzeh, Khaled W ^a   Darga, Thomas E ^a   Mauceri, Helena J ^a   Fu, Yang Xin ^a   Kron, Stephen J ^a   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; BETA INTERFERON; CD8 ANTIGEN; CD86 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN P21; RANTES; TUMOR CELL VACCINE; VELIPARIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA REPAIR; GENE; IMMUNE RESPONSE; IONIZING RADIATION; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS ADENOCARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; RADIOSENSITIZATION; SENESCENCE ASSOCIATED SECRETORY PHENOTYPE GENE; SENESCENT TUMOR CELL; TUMOR CELL;

MUS;

EID: 84860518120     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.19     Document Type: Article

References (38)

1. Apetoh, L, Ghiringhelli, F, Tesniere, A, Obeid, M, Ortiz, C, Criollo, A et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059. (Pubitemid 47517504)
2. Ma, Y, Kepp, O, Ghiringhelli, F, Apetoh, L, Aymeric, L, Locher, C et al. (2010). Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 22: 113-124.
3. Reits, EA, Hodge, JW, Herberts, CA, Groothuis, TA, Chakraborty, M, Wansley, EK et al. (2006). Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203: 1259-1271. (Pubitemid 43736595)
4. Shiao, SL and Coussens, LM (2010). The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 15: 411-421.
5. Lugade, AA, Sorensen, EW, Gerber, SA, Moran, JP, Frelinger, JG and Lord, EM (2008). Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180: 3132-3139.
6. Lee, Y, Auh, SL, Wang, Y, Burnette, B, Wang, Y, Meng, Y et al. (2009). Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114: 589-595.
7. Demaria, S, Ng, B, Devitt, ML, Babb, JS, Kawashima, N, Liebes, L et al. (2004). Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58: 862-870. (Pubitemid 38221143)
8. Schreiber, V, Dantzer, F, Ame, JC and de Murcia, G (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517-528. (Pubitemid 44036457)
9. Ashworth, A (2008). A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785-3790.
10. Efimova, EV, Mauceri, HJ, Golden, DW, Labay, E, Bindokas, VP, Darga, TE et al. (2010). Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res 70: 6277-6282.
11. Barreto-Andrade, JC, Efimova, EV, Mauceri, HJ, Beckett, MA, Sutton, HG, Darga, TE et al. (2011). Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther 10: 1185-1193.
12. Nardella, C, Clohessy, JG, Alimonti, A and Pandolfi, PP (2011). Pro-senescence therapy for cancer treatment. Nat Rev Cancer 11: 503-511.
13. Kahlem, P, Dörken, B and Schmitt, CA (2004). Cellular senescence in cancer treatment: friend or foe? J Clin Invest 113: 169-174. (Pubitemid 38544199)
14. Roninson, IB (2003). Tumor cell senescence in cancer treatment. Cancer Res 63: 2705-2715. (Pubitemid 36667137)
15. Rodier, F, Coppé, JP, Patil, CK, Hoeijmakers, WA, Muñoz, DP, Raza, SR et al. (2009). Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973-979.
16. Coppé, JP, Desprez, PY, Krtolica, A and Campisi, J (2010). The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5: 99-118.
17. Rodier, F and Campisi, J (2011). Four faces of cellular senescence. J Cell Biol 192: 547-556.
18. Ohanna, M, Giuliano, S, Bonet, C, Imbert, V, Hofman, V, Zangari, J et al. (2011). Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 25: 1245-1261.
19. Meng, Y, Beckett, MA, Liang, H, Mauceri, HJ, van Rooijen, N, Cohen, KS et al. (2010). Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res 70: 1534-1543.
20. Meng, Y, Mauceri, HJ, Khodarev, NN, Darga, TE, Pitroda, SP, Beckett, MA et al. (2010). Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-betadependent activation of antigen-specific CD8+ T cells. Mol Ther 18: 912-920.
21. Xue, LY, Butler, NJ, Makrigiorgos, GM, Adelstein, SJ and Kassis, AI (2002). Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA 99: 13765-13770. (Pubitemid 35215455)
22. Orjalo, AV, Bhaumik, D, Gengler, BK, Scott, GK and Campisi, J (2009). Cell surfacebound IL-1alpha is an upstream regulator of the senescence- associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci USA 106: 17031-17036.
23. Novakova, Z, Hubackova, S, Kosar, M, Janderova-Rossmeislova, L, Dobrovolna, J, Vasicova, P et al. (2010). Cytokine expression and signaling in drug-induced cellular senescence. Oncogene 29: 273-284.
24. Xue, W, Zender, L, Miething, C, Dickins, RA, Hernando, E, Krizhanovsky, V et al. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660. (Pubitemid 46232886)
25. Rakhra, K, Bachireddy, P, Zabuawala, T, Zeiser, R, Xu, L, Kopelman, A et al. (2010). CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18: 485-498.
26. Campisi, J and d'Adda di Fagagna, F (2007). Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740. (Pubitemid 47312822)
27. Evan, GI and d'Adda di Fagagna, F (2009). Cellular senescence: hot or what? Curr Opin Genet Dev 19: 25-31.
28. Aguilar-Quesada, R, Muñoz-Gámez, JA, Martín-Oliva, D, Peralta-Leal, A, Quiles-Pérez, R, Rodríguez-Vargas, JM et al. (2007). Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem 14: 1179-1187. (Pubitemid 46739319)
29. Krizhanovsky, V, Xue, W, Zender, L, Yon, M, Hernando, E and Lowe, SW (2008). Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol 73: 513-522.
30. Ghiringhelli, F, Apetoh, L, Tesniere, A, Aymeric, L, Ma, Y, Ortiz, C et al. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178.
31. Strome, SE, Voss, S, Wilcox, R, Wakefield, TL, Tamada, K, Flies, D et al. (2002). Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 62: 1884-1889. (Pubitemid 34408517)
32. Tirapu, I, Lewis, A, Kreutz, M, McLinden, H and Diebold, SS (2008). Freeze-andthaw-disrupted tumour cells impair the responsiveness of DC to TLR stimulation. Eur J Immunol 38: 2740-2750.
33. Schnurr, M, Scholz, C, Rothenfusser, S, Galambos, P, Dauer, M, Röbe, J et al. (2002). Apoptotic pancreatic tumor cells are superior to cell lysates in promoting crosspriming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res 62: 2347-2352. (Pubitemid 34411716)
34. Powell, C, Mikropoulos, C, Kaye, SB, Nutting, CM, Bhide, SA, Newbold, K et al. (2010). Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 36: 566-575.
35. Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543. (Pubitemid 23111402)
36. Blank, C, Brown, I, Peterson, AC, Spiotto, M, Iwai, Y, Honjo, T et al. (2004). PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64: 1140-1145. (Pubitemid 38176921)
37. Spiotto, MT, Yu, P, Rowley, DA, Nishimura, MI, Meredith, SC, Gajewski, TF et al. (2002). Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17: 737-747. (Pubitemid 35477793)
38. Passos, JF and von Zglinicki, T (2007). Methods for cell sorting of young and senescent cells. Methods Mol Biol 371: 33-44. (Pubitemid 350183416)